WST 241018 320.00C (WST241018C320000) Stock Options, News & Quotes

3.70
+0.50+15.63%

15min DelayClose Sep 27 16:00 ET

3.70High3.70Low

SymbolStock Name

Latest PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

The Thinker

Sep 18 19:43

Market Sentiment Wavers as Bursa Malaysia, U.S. Stocks Decline Amid Fed Cut

CLICK HERE: TYNKR LAB™
Both the U.S. and Bursa Malaysia markets experienced volatility amidst global economic uncertainty and investor caution ahead of the U.S. Federal Reserve’s expected interest rate cut. While the U.S. stock market saw declines, Bursa Malaysia ended lower as well, with losses driven by various sectoral pressures.
U.S. Stock Market
Performance Overview
U.S. equities closed lower on Wednesday, with $Dow Jones Industrial Average (.DJI.US)$ falling b...

Aggressive 50bp rate cut: How long will the market frenzy last?

Stock_Drift

Jun 22 15:53

$West Pharmaceutical Services (WST.US)$

Moomoo Recap US

Feb 15 15:36

Columns Wall Street Today | S&P Makes Another Record After Soft Retail Before Inflation Friday

RECAP
U.S. equity indexes rose after Thursday, with the $Nasdaq Composite Index (.IXIC.US)$ lagging the pack, as investors weighed retail sales and jobless claims ahead of more inflation data this week.
The $S&P 500 Index (.SPX.US)$ rose 0.58% to 5,029, a new closing high with the $Dow Jones Industrial Average (.DJI.US)$ up 0.91% to 38,664. The $Nasdaq Composite Index (.IXIC.US)$ was moderately higher at 15,906, af...

Moomoo AI

Feb 15 09:09

Analysts worry about the company's shifting tone and the enduring effect of clients' inventory management on West's finances. Doubts also arise about the company's demand visibility and if current trends suggest a fundamental issue in West's base business.

West Pharmaceutical Stock Tumbles on Weak 2024 Outlook -- Barrons.com

Moomoo AI

Feb 11 11:09

Jefferies analyst David Windley sees FDA approvals of GLP-1s for obesity treatment as a huge opportunity for the manufacturing supply chain. He also notes high rivalry in the injectable fill/finish market. Windley upgraded West Pharmaceutical to Buy, raising its price target by 66% to $536, citing its global footprint and capacity to meet growing GLP-1s demand.

Booming Weight-loss Drug Market to Lift "pick-and-shovel" Plays: Jefferies